volume 11, issue Suppl 1, PP38 2008
DOI: 10.1186/1758-2652-11-s1-p38
View full text
|
|
Share

Abstract: To evaluate the efficacy of raltegravir (RAL) and etravirine (ETV) in addition to a background optimised treatment in patients (pts) with persistent viremia while on darunavir (DRV) and multidrug resistant virus. MethodsProspective, pilot, open-label, single arm study evaluating pts with at least 3-drug class exposure, plasma HIV-RNA (VL) >1000 c/ml while on a DRV-containing regimen. Pts were given RAL and ETV in addition to optimized background therapy (OBT). Primary end-point was the proportion of pts with …

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
1
0

Publication Types

Select...

Relationship

0
0

Authors

Journals